Four things to know:
1. The study, published in Pain Physician Journal, studied Discseel for treating chronic low back pain and sciatica, according to a news release.
2. The study of 725 individuals showed statistically significant improvement in all measured outcomes at 1-, 2- and 3-years after undergoing the procedure.
3. Patients enrolled in the study were eligible if they failed “a combination of at least four prior treatments including surgical fusion, laminectomy, discectomy, stem cell injection, and other invasive treatments,” Kevin Pauza, MD, the study’s lead investigator said in the release.
4. Discseel is an outpatient spine procedure that uses a Fibrin biologic drug to seal disc damage and stimulate growth.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
